Suppr超能文献

低发病人群中尤因家族性肿瘤的反应预测及预后因素

Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population.

作者信息

Yonemori Kan, Yamaguchi Umio, Kaneko Masayuki, Uno Hajime, Takeuchi Masahiro, Ando Masashi, Fujiwara Yasuhiro, Hosono Ako, Makimoto Atsushi, Hasegawa Tadashi, Yokoyama Ryouhei, Nakatani Fumihiko, Kawai Akira, Beppu Yasuo, Chuman Hirokazu

机构信息

Breast and Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

出版信息

J Cancer Res Clin Oncol. 2008 Mar;134(3):389-95. doi: 10.1007/s00432-007-0295-9. Epub 2007 Aug 9.

Abstract

PURPOSE

There is some unknown reason Ewing family of tumors (EFTs) is much less common on Asia and Africa than in the Western Caucasian population. This study analyzed the prediction of response and prognostic factors for Ewing family of tumors (EFTs) in an Asian population with a low incidence.

METHODS

We retrospectively reviewed 94 patients with EFTs between 1978 and 2006. Fifteen patients received local therapy only. Statistical analyses were performed for 79 patients, including those who received systemic chemotherapy, to identify factors related to chemotherapy responsiveness, event-free survival, and overall survival.

RESULTS

Of the 79 patients whose records were analyzed, the 5-year event-free rate and overall survival (OS) rate were 41 and 54%, respectively. The response rate to first-line chemotherapy was 61% in 70 patients with assessable lesions. A significant predictor of response was existence of a non-pelvic primary tumor (P = 0.04). Significant prognostic factors for OS were age, performance status, and metastases at the time of diagnosis (P < 0.01, respectively). Fifty-four patients had disease progression or recurrence after first-line treatment. The time to progression was 3.4 months after salvage treatment. Progression during first-line treatment was significantly associated with time to progression after salvage treatment (P = 0.01). All patients treated without chemotherapy in first-line treatment were recurred with poor prognosis.

CONCLUSION

A non-pelvic primary tumor was a favorable predictor of responsiveness to chemotherapy. Chemo-resistant patients might less benefit from second line chemotherapy. Chemotherapy in first-line treatment should not be omitted, even if primary tumor was extirpated completely.

摘要

目的

尤因家族性肿瘤(EFTs)在亚洲和非洲的发病率远低于西方白种人群,原因尚不明确。本研究分析了亚洲低发病率人群中尤因家族性肿瘤(EFTs)的反应预测及预后因素。

方法

我们回顾性分析了1978年至2006年间94例EFTs患者。15例仅接受了局部治疗。对79例患者进行了统计分析,包括接受全身化疗的患者,以确定与化疗反应性、无事件生存期和总生存期相关的因素。

结果

在分析记录的79例患者中,5年无事件生存率和总生存率分别为41%和54%。70例有可评估病灶的患者对一线化疗的反应率为61%。反应的一个重要预测因素是非盆腔原发性肿瘤的存在(P = 0.04)。总生存期的重要预后因素是年龄、体能状态和诊断时的转移情况(分别为P < 0.01)。54例患者在一线治疗后出现疾病进展或复发。挽救治疗后疾病进展时间为3.4个月。一线治疗期间的进展与挽救治疗后疾病进展时间显著相关(P = 0.01)。所有一线治疗未接受化疗的患者均复发,预后较差。

结论

非盆腔原发性肿瘤是化疗反应性的有利预测因素。化疗耐药患者可能从二线化疗中获益较少。即使原发性肿瘤已完全切除,一线治疗中的化疗也不应省略。

相似文献

1
Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population.
J Cancer Res Clin Oncol. 2008 Mar;134(3):389-95. doi: 10.1007/s00432-007-0295-9. Epub 2007 Aug 9.
2
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
6
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Cochrane Database Syst Rev. 2015 Oct 5;2015(10):CD006301. doi: 10.1002/14651858.CD006301.pub4.
10
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

引用本文的文献

1
Role of radiation therapy in the multidisciplinary management of Ewing's Sarcoma of bone in pediatric patients: An effective treatment for local control.
Rep Pract Oncol Radiother. 2011 Mar 12;16(3):103-9. doi: 10.1016/j.rpor.2011.01.006. eCollection 2011.
2
Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT.
Br J Cancer. 2013 Jul 9;109(1):195-206. doi: 10.1038/bjc.2013.168. Epub 2013 Jun 25.
3
The clinical use of biomarkers as prognostic factors in Ewing sarcoma.
Clin Sarcoma Res. 2012 Feb 8;2(1):7. doi: 10.1186/2045-3329-2-7.

本文引用的文献

2
Single center experience of treatment of Ewing's family of tumors in Japan.
J Orthop Sci. 2006 Jan;11(1):34-41. doi: 10.1007/s00776-005-0974-9.
4
VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
Am J Clin Oncol. 2004 Oct;27(5):529-34. doi: 10.1097/01.coc.0000135815.94162.83.
5
Treatment of Ewing sarcoma family of tumors: current status and outlook for the future.
Med Pediatr Oncol. 2003 May;40(5):276-87. doi: 10.1002/mpo.10240.
7
Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma.
Med Pediatr Oncol. 2003 Mar;40(3):141-7. doi: 10.1002/mpo.10248.
9
Localised Ewing sarcoma/PNET of bone--prognostic factors and international data comparison.
Med Pediatr Oncol. 2002 Dec;39(6):586-93. doi: 10.1002/mpo.10212.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验